Hereditary hemochromatosis and risk of ischemic heart disease: A prospective study and a case-control study

Circulation

Volumn 112, Issue 2, 2005, Pages 185-193

  Ellervik, Christina ^a   Tybjærg Hansen, Anne ^b,c   Grande, Peer ^b   Appleyard, Merete ^c   Nordestgaard, Børge G ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Cardiovascular diseases; Case control studies; Hemochromatosis; Prospective studies

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; FEMALE; GENETIC RISK; GENOTYPE; HEART INFARCTION; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EPIDEMIOLOGY, MOLECULAR; FAMILY HEALTH; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; ODDS RATIO; PROSPECTIVE STUDIES; RISK;

EID: 22144487720     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.496075     Document Type: Article

References (27)

1. Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation. 1999;99:852-854.
2. Sullivan JL, Zacharski LR. Hereditary haemochromatosis and the hypothesis that iron depletion protects against ischemic heart disease. Eur J Clin Invest. 2001;31:375-377.
3. Beutler E, Bothwell TH, Charlton RW, Motulsky AG. Hereditary hemochromatosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3127-3162.
4. de Valk B, Marx JJM. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999;159:1542-1548.
5. Annichino-Bizzacchi JM, Saad STO, Arruda VR, Ramires JAF, Siqueira LH, Chiaparini LC, Mansur AP. C282Y mutation in the HLA-H gene is not a risk factor for patients with myocardial infarction. J Cardiovasc Risk. 2000;7:37-40.
6. Battiloro E, Ombres D, Pascale E, D'Ambrosio E, Verna R, Area M. Haemochromatosis gene mutations and risk of coronary artery disease. Eur J Hum Genet. 2000;8:389-392.
7. Candore G, Balistreri CR, Lio D, Mantovani V, Colonna-Romano G, Chiappelli M, Tampieri C, Licastro F, Branzi A, Averna M, Caruso M, Hoffman E, Caruso C. Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. Blood Cells Mol Dis. 2003;31:57-62.
8. Claeys D, Waiting M, Julmy F, Wuillemin WA, Meyer BJ. Haemochromatosts mutations and ferritin in myocardial infarction: a case-control study. Eur J Clin Invest. 2002;32:3-8.
9. Fox CJ, Cullen DJ, Knuiman MW, Cumpston GN, Divitini ML, Rossi E, Gochee PA, Powell LW, Olynyk JK. Effects of body iron stores and haemochromatosis genotypes on coronary heart disease outcomes in the Busselton Health Study. J Cardiovasc Risk, 2002;9:287-293.
10. Franco RF, Zago MA, Trip MD, ten Gate H, van den Ende A, Prins MH, Kastelein JJP, Reitsma PH. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br J Haemalol. 1998;102: 1172-1175.
11. Hetet G, Elbaz A, Gariepy J, Nicaud V, Arveiler D, Morrison C, Kee F, Evans A, Simon A, Amarenco P, Cambien F, Grandchatnp B. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest. 2001;31:382-388.
12. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2001;154:739-746.
13. Roest M, van der Schouw YT, de Valk B, Marx JJM, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268-1273.
14. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation. 1999;100:1274-1279.
15. van Aken MO, de Craen AJM, Gussekloo J, Moghaddam PH, Vandenbroucke JP, Heijmans BT, Slagboom PE, Westendorp RGJ. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus Study. Eur J Clin Invest. 2002;32:750-754.
16. Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E. Prevalence of coronary heart disease associated with HFE mutations in adults attending a health appraisal center. Am J Med. 2002;113:472-479.
17. Gunn IR, Maxwell FK, Gaffney D, McMahon AD, Packard CJ. Haemochromatosis gene mutations and risk of coronary heart disease: a West Of Scotland Coronary Prevention Study (WOSCOPS) substudy. Heart. 2004;90:304-306.
18. Campbell S, George DK, Robb SD, Spooner R, McDonagh TA, Dargie HJ, Mills PR. The prevalence of haemochromatosis gene mutations in the West of Scotland and their relation to ischaemic heart disease. Heart. 2003;89:1023-1026.
19. Calado RT, Franco RF, Pazin-Filho A, Simoes MV, Marin-Neto JA, Zago MA. FIFE gene mutations in coronary atherothrombotic disease. Braz J Med Biol Res. 2000;33:301-306.
20. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Ellis MC, Fullan A, Himon LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risen NJ, Bacon BR. A novel MHC class I-like gene is mutated in patients with hereditary haemochroniatosis. Nat Genet. 1996;13: 399-408.
21. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914-2919.
22. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329-337.
23. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, Larsen LE, Appleyard M, Frandsen M, Petersen P, Schlichting P, Saermark T, Tybjaerg-Hansen A, Birgens H. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001;358: 1405-1409.
24. The Copenhagen City Heart Study Group. The Copenhagen City Heart Study: Østerbroundersøgelsen: a book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). Scand J Soc Med Suppl. 1989;41:1-160.
25. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The Copenhagen City Heart Study: Østerbroundersøgelsen: tables with data from the third examination 1991-1994. Eur Heart J. 2001;3:1-83.
26. Management of stable angina pectoris: Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 1997;18: 394-413.
27. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.